BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:XellSmart Bio-Pharmaceutical (Suzhou) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies XellSmart Bio-Pharmaceutical (Suz
 hou)'s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07166757-1737@assetmemo.bio
DTSTAMP:20261121T005949Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:XS-411: Phase 1/2 readout est. (NCT07166757)
DESCRIPTION:XS-411\, phase 1/2\, Parkinson's Disease.\nStudy: Clinical Stud
 y to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease\nEstim
 ated primary completion: 30 March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/xs-411#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07166757
URL:https://assetmemo.bio/drug/xs-411#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
